Beyond Air Dirección

Dirección controles de criterios 3/4

El CEO de Beyond Air es Steve Lisi , nombrado en Jun 2017, tiene una permanencia de 7.42 años. compensación anual total es $1.73M, compuesta por 37.5% salario y 62.5% primas, incluidas acciones y opciones de la empresa. posee directamente un 4.5% de las acciones de la empresa, por valor de €1.69M. La antigüedad media del equipo directivo y de la junta directiva es de 2.3 años y 7 años, respectivamente.

Información clave

Steve Lisi

Chief Executive Officer (CEO)

US$1.7m

Compensación total

Porcentaje del salario del CEO	37.5%
Permanencia del CEO	7.4yrs
Participación del CEO	4.5%
Permanencia media de la dirección	2.3yrs
Promedio de permanencia en la Junta Directiva	7yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Steve Lisi en comparación con los beneficios de Beyond Air?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2024	n/a	n/a	-US$55m
Jun 30 2024	n/a	n/a	-US$58m
Mar 31 2024	US$2m	US$650k	-US$60m
Dec 31 2023	n/a	n/a	-US$67m
Sep 30 2023	n/a	n/a	-US$63m
Jun 30 2023	n/a	n/a	-US$59m
Mar 31 2023	US$7m	US$650k	-US$56m
Dec 31 2022	n/a	n/a	-US$56m
Sep 30 2022	n/a	n/a	-US$51m
Jun 30 2022	n/a	n/a	-US$47m
Mar 31 2022	US$6m	US$450k	-US$43m
Dec 31 2021	n/a	n/a	-US$28m
Sep 30 2021	n/a	n/a	-US$26m
Jun 30 2021	n/a	n/a	-US$23m
Mar 31 2021	US$2m	US$450k	-US$23m
Dec 31 2020	n/a	n/a	-US$23m
Sep 30 2020	n/a	n/a	-US$22m
Jun 30 2020	n/a	n/a	-US$21m
Mar 31 2020	US$1m	US$450k	-US$20m
Dec 31 2019	n/a	n/a	-US$15m
Sep 30 2019	n/a	n/a	-US$13m
Jun 30 2019	n/a	n/a	-US$11m
Mar 31 2019	US$3m	US$450k	-US$7m
Dec 31 2018	n/a	n/a	-US$5m
Sep 30 2018	n/a	n/a	-US$5m
Jun 30 2018	n/a	n/a	-US$10m
Mar 31 2018	US$537k	US$130k	-US$11m
Dec 31 2017	US$2m	US$163k	-US$18m

Compensación vs. Mercado: La compensación total de Steve($USD1.73M) está por encima de la media de empresas de tamaño similar en el mercado German ($USD474.54K).

Compensación vs. Ingresos: La compensación de Steve ha sido consistente con los resultados de la empresa en el último año.

CEO

Steve Lisi (53 yo)

7.4yrs

Permanencia

US$1,733,000

Compensación

Mr. Steven Adam Lisi, also known as Steve, has been the Chief Executive Officer of Beyond Air, Inc. (formerly known as AIT Therapeutics, Inc.) since June 14, 2017. Mr. Lisi serves as Chief Executive Office...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Steven Lisi	CEO & Chairman of the Board	7.4yrs	US$1.73m	4.5% € 1.7m
Michael Gaul	Chief Operating Officer	2.3yrs	US$799.00k	0.090% € 34.0k
Amir Avniel	Chief Executive Officer of NeuroNOS	less than a year	US$952.00k	0% € 0
Douglas Larson	CFO, Principal Financial Officer & Principal Accounting Officer	3.2yrs	US$1.13m	0.026% € 9.7k
Edward Barger	Head of Investor Relations	no data	sin datos	sin datos
Andrew Colin	Senior Medical Director Global Clinical Leadership & Member of Scientific Advisory Board	2.9yrs	sin datos	sin datos
David Webster	Chief Commercial Officer	less than a year	sin datos	sin datos
John Jett	Head of Research & Clinical Development	less than a year	sin datos	sin datos
Adam Newman	Corporate Secretary	no data	US$643.57k	sin datos

2.3yrs

Permanencia media

54yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 48L se considera experimentado (2.3 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Steven Lisi	CEO & Chairman of the Board	7.8yrs	US$1.73m	4.5% € 1.7m
Andrew Colin	Senior Medical Director Global Clinical Leadership & Member of Scientific Advisory Board	11.8yrs	sin datos	sin datos
Yoori Lee	Independent Director	6.8yrs	US$51.30k	0.018% € 6.6k
Robert Carey	Independent Director	5.8yrs	US$102.60k	6.31% € 2.4m
Ron Bentsur	Independent Director	7.8yrs	US$51.30k	0.20% € 75.4k
William Forbes	Independent Director	6.3yrs	US$51.30k	0.021% € 7.7k
Yossef Av-Gay	Member of Scientific Advisory Board	6.8yrs	US$75.00k	sin datos
David Greenberg	Member of Scientific Advisory Board	no data	sin datos	sin datos
Richard Malley	Member of Scientific Advisory Board	no data	sin datos	sin datos
Erick Lucera	Independent Director	7.3yrs	US$51.30k	0.060% € 22.7k
Hannah Blau	Member of Scientific Advisory Board	no data	sin datos	sin datos
Stacey Martiniano	Member of Scientific Advisory Board	no data	sin datos	sin datos

7.0yrs

Permanencia media

60yo

Promedio de edad

Junta con experiencia: La junta directiva de 48L se considera experimentada (7 años de antigüedad promedio).

Beyond Air Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Beyond Air, Inc., Annual General Meeting, Dec 09, 2024

Beyond Air Appoints David Webster as Chief Commercial Officer, Effective from July 8, 2024

Beyond Air, Inc., Annual General Meeting, Mar 08, 2024

Independent Director recently bought €1.8m worth of stock

Independent Director recently bought €224k worth of stock

Independent Director recently bought €117k worth of stock

Recent updates

Beyond Air, Inc. announced that it has received $3.35 million in funding from Avenue Capital Group, LLC

Second quarter 2025 earnings released: US$0.28 loss per share (vs US$0.51 loss in 2Q 2024)

New major risk - Shareholder dilution

Beyond Air, Inc. to Report Q2, 2025 Results on Nov 11, 2024

Beyond Air, Inc., Annual General Meeting, Dec 09, 2024

Beyond Air, Inc. Withdraws Its Previous Revenue Guidance for Fiscal Year 2025

Beyond Air, Inc. Provides Earnings Guidance for the Year 2025

Beyond Air, Inc. to Report Q1, 2025 Results on Aug 06, 2024

Beyond Air, Inc. announced that it has received $0.128 million in funding

Beyond Air, Inc.(NasdaqCM:XAIR) dropped from Russell Small Cap Comp Value Index

New major risk - Financial position

Beyond Air, Inc. Updates Revenue Guidance for the Fiscal Year 2025

Beyond Air Appoints David Webster as Chief Commercial Officer, Effective from July 8, 2024

Beyond Air, Inc. to Report Q4, 2024 Results on Jun 24, 2024

Beyond Air, Inc. has completed a Follow-on Equity Offering in the amount of $16.000003 million.

Beyond Air, Inc. has filed a Follow-on Equity Offering in the amount of $16.000003 million.

New major risk - Financial position

Beyond Air, Inc. has filed a Follow-on Equity Offering.

New major risk - Revenue and earnings growth

Beyond Air, Inc., Annual General Meeting, Mar 08, 2024

Beyond Air, Inc. to Report Q3, 2024 Results on Feb 12, 2024

Independent Director recently bought €1.8m worth of stock

New major risk - Financial position

Beyond Air, Inc. to Report Q2, 2024 Results on Nov 13, 2023

Beyond Air, Inc. Announces Publication of Positive New Preclinical Data for the Treatment of Autism Spectrum Disorder

Independent Director recently bought €224k worth of stock

New minor risk - Market cap size

New major risk - Share price stability

No longer forecast to breakeven

Beyond Air, Inc. to Report Q1, 2024 Results on Aug 10, 2023

New major risk - Revenue and earnings growth

New minor risk - Shareholder dilution

No longer forecast to breakeven

Beyond Air, Inc. announced that it expects to receive $40 million in funding

Beyond Air, Inc. to Report Q4, 2023 Results on Jun 22, 2023

Forecast to breakeven in 2026

Forecast to breakeven in 2026

Independent Director recently bought €117k worth of stock

Forecast to breakeven in 2026

CEO & Chairman of the Board recently bought €61k worth of stock

Independent Director recently bought €56k worth of stock

Beyond Air, Inc., Annual General Meeting, Mar 09, 2023

Beyond Air, Inc. to Report Q3, 2023 Results on Feb 09, 2023

Independent Director recently bought €110k worth of stock

Independent Director recently bought €167k worth of stock

Independent Director recently bought €284k worth of stock

No longer forecast to breakeven

Insufficient new directors

No longer forecast to breakeven

Beyond Air® Announces Positive Data for Inhaled Nitric Oxide (NO) to Treat COVOD-19 with LungFit® PRO in A Poster Presentation At IDWeek 2022

Beyond Air, Inc. to Report Q2, 2023 Results on Nov 08, 2022

Beyond Air, Inc. Announces Positive Data from At-Home Pilot Study in Patients with Refractory NTM Lung Infection Treated with (NO) Using the LungFit® GO at the CHEST Annual Meeting 2022

Beyond Air Announces Annals of the American Thoracic Society Published Review of the Third Pilot Study of High Dose Nitric Oxide for Bronchiolitis

Beyond Air, Inc. to Report Q1, 2023 Results on Aug 11, 2022

Beyond Air, Inc. Appoints Michael Gaul as Chief Operating Officer

Independent Director recently bought €1.1m worth of stock

Beyond Air, Inc. Announces Executive Changes

No longer forecast to breakeven

Full year 2022 earnings released: US$1.68 loss per share (vs US$1.27 loss in FY 2021)

Beyond Air’s LungFit PH Receives FDA Approval to Treat Term and Near-Term Neonates with Hypoxic Respiratory Failure

Beyond Air® Presents Positive Study Update from the At-Home LungFit® GO Pilot Study for Nontuberculous Mycobacterial Lung Disease at the American Thoracic Society International Conference 2022

Beyond Air, Inc. to Report Q4, 2022 Results on Jun 16, 2022

Insufficient new directors

Beyond Air, Inc. Reports Positive Long-Term Safety Data for High Concentration Inhaled Nitric Oxide in Bronchiolitis at the Pediatric Academic Societies Meeting 2022

Independent Director recently bought €123k worth of stock

Insufficient new directors

Independent Director recently bought €158k worth of stock

Independent Director recently bought €121k worth of stock

Insufficient new directors